Valuation : Relay Therapeutics, Inc.

Market Cap 4.14B 3.56B 3.36B 3.06B 5.72B 396B 5.77B 40B 15.4B 201B 15.54B 15.21B 638B P/E 2026 *
-11.8x
P/E 2027 * -11.7x
Enterprise Value 3.57B 3.07B 2.9B 2.64B 4.93B 341B 4.98B 34.49B 13.27B 173B 13.4B 13.11B 550B EV / Sales 2026 *
339x
EV / Sales 2027 * 223x
Free-Float
91.35%
Yield 2026 *
-
Yield 2027 * -
1 day+1.23%
1 week-0.63%
Current month+2.77%
1 month-5.27%
3 months+40.03%
6 months+76.71%
Current year+123.29%
1 week 18.1
Extreme 18.1
19.28
1 month 17.96
Extreme 17.96
21.27
Current year 7.01
Extreme 7.01
21.27
1 year 3.88
Extreme 3.885
21.27
3 years 1.78
Extreme 1.775
21.27
5 years 1.78
Extreme 1.775
38.15
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 01/03/2017
Director of Finance/CFO 49 01/04/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 04/05/2015
Director/Board Member 66 01/07/2016
Director/Board Member 52 01/03/2017
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 A Sell

Chief Financial Officer

-17,717 0.0081%
9/8/26 A Sell

Chief Executive Officer

-48,199 0.0220%
9/8/26 A Sell

Chief Technology Officer

-8,530 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+1.23%-0.63%+365.27%+94.14% 4.09B
-0.56%-8.08%-3.88%+10.58% 46.38B
-2.08%-3.57%+402.72%+533.09% 44.51B
+0.12%-5.27%+39.94%+20.50% 42.3B
-2.62%-5.76%+8.88%+77.44% 39.91B
-1.26%-3.37%+11.87%+40.55% 32.79B
+0.16%-3.65% - - 17.13B
-0.54%-1.72%+22.34%+115.10% 16.36B
-0.03%-3.46%+12.68%+30.90% 14.31B
-1.92%-6.94%+78.12%+36.68% 13.29B
Average -0.75%-3.93%+104.21%+106.55% 27.11B
Weighted average by Cap. -1.06%-4.48%+91.59%+128.79%

Financials

2026 *2027 *
Net sales 10.53M 9.06M 8.55M 7.79M 14.55M 1.01B 14.69M 102M 39.17M 511M 39.55M 38.69M 1.62B 16.56M 14.24M 13.44M 12.24M 22.88M 1.58B 23.09M 160M 61.58M 803M 62.18M 60.82M 2.55B
Net income -320M -276M -260M -237M -443M -30.64B -447M -3.1B -1.19B -15.54B -1.2B -1.18B -49.36B -347M -299M -282M -257M -480M -33.21B -484M -3.36B -1.29B -16.85B -1.3B -1.28B -53.51B
Net Debt -571M -491M -463M -422M -789M -54.56B -796M -5.52B -2.12B -27.68B -2.14B -2.1B -87.9B -442M -380M -359M -327M -611M -42.26B -616M -4.27B -1.64B -21.43B -1.66B -1.62B -68.08B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
202
Date Price Change Volume
10/09/26 $18.89 +1.23% 3,000,713
09/09/26 $18.66 -2.35% 6,061,328
08/09/26 $19.11 +0.37% 5,029,838
04/09/26 $19.04 +0.16% 2,054,847
03/09/26 $19.01 +2.70% 2,716,788
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
18.89USD
Average target price
27.08USD
Spread / Average Target
+43.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!